Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14359693 | 0.86 | GAA (0.59) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL3087061 | 0.85 | GAA (0.73) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL10967899 | 0.84 | GAA (0.72) | GAAKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL32665587 | 0.82 | TRPV1 (0.54) | GAAKMT2AMEN1L3MBTL1LMNA | |
| SCHEMBL28822072 | 0.82 | L3MBTL1 (0.64) | GAAKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL1186049 | 0.81 | GAA (0.68) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL414454 | 0.81 | GAA (0.68) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL392625 | 0.81 | ALDH1A1 (0.82) | GAAKMT2AMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL622501 | 0.81 | GAA (0.68) | GAAKMT2AMEN1L3MBTL1MCL1 | |
| SCHEMBL21778866 | 0.81 | MAPT (0.67) | KMT2AMEN1ALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036718-A | ALK5 inhibitor and preparation method and application thereof | 安炎达医药技术(广州)有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250333395-A1 | BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | Agomab Spain, S.L.U. (ES) | 2025-10-30 | — | — | US | disclosed |
| US-12297186-B2 | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | Agomab Spain, S.L.U. (ES) | 2025-05-13 | — | — | US | disclosed |
| WO-2025093589-A1 | HETEROARYL AMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-05-08 | — | — | WO | disclosed |
| CN-119161306-A | Bicycloacetamide structural compound, preparation method and pharmaceutical application thereof | 河南大学 | 2024-12-20 | — | — | CN | disclosed |
| US-20240368001-A1 | SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-11-07 | — | — | US | disclosed |
| CN-117164418-B | Alpha-halogenated ketone, efficient synthesis method and application thereof | 徐州医科大学 | 2024-07-02 | — | — | CN | disclosed |
| US-11987506-B2 | Salt recovery solution and processes of use thereof | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-05-21 | — | — | US | disclosed |
| CN-114787145-B | Benzamide derivatives as transforming growth factor-beta receptor I/ALK5 inhibitors | 阿戈麦布西班牙股份有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117003744-A | Five-membered and six-membered compound, intermediate, preparation method, composition and application | 厦门市博瑞来医药科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-0757051-B1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6071899-A | Azetidinone derivatives for the treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-06-06 | — | — | US | disclosed |
| US-5990102-A | Substituted azetidin-2-ones for treatment of atherosclerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-23 | — | — | US | disclosed |
| EP-0799200-A1 | SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-08 | — | — | EP | disclosed |
| EP-0788478-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-13 | — | — | EP | disclosed |
| EP-0757051-A1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-05 | — | — | EP | disclosed |
| WO-1996019451-A1 | SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-27 | — | — | WO | disclosed |
| WO-1996013484-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-09 | — | — | WO | disclosed |
| WO-1995029155-A1 | NOVEL ANTITUMOUR COMPOUNDS WITH ANTIMITOTIC ACTIVITY | PHARMACIA AB (SE) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297186-B2 | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5 | TGFBR2, TGFBR1, ACVR1 | GAA 650/4885KMT2A 2848/4885MEN1 2998/4885 |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | MRPL21, MRPS2, MRPS28 | GAA 2407/4885KMT2A 2222/4885MEN1 3773/4885 |
| US-20250333395-A1 | BENZYLAMIDE DERIVATIVES AS INHIBITORS OF TRANSFORMING GROWTH FACTOR-BETA RECEPTOR I/ALK5 | TGFBR2, TGFBR1, ACVR1 | GAA 650/4885KMT2A 2848/4885MEN1 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.